Fulgent Genetics, Inc. (FLGT) income statement
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3044% below fair value
$25.13+0.92 (+3.80%)
Close on Nov 18, 2026Market cap $691.46MP/E –Yield –
Fulgent Genetics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 35.6%
- Operating margin
- -37.7%
- Net margin
- -26.0%
- Return on equity, FY2025
- -5.4%
Financial strength
- Current ratio
- 6.34
- Debt to equity
- 0.00
- Debt to assets
- 0.1%
- Cash to current liabilities
- 36.7%
Valuation
- P/E ratio
- –
- Price to sales
- 2.13
- Price to book
- 0.69
- Dividend yield
- –
See a number that looks wrong?